1
|
Aspros K, Nelson A, Ye Z, Sun Z, Chernukhin I, Carroll J, Ingle J, Goetz M, Hawse J. Abstract P5-05-03: Estrogen receptor beta elicits anti-cancer effects in triple negative breast cancer through suppression of NFκB signaling. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p5-05-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Triple Negative Breast Cancer (TNBC) affects approximately 15-20% of BC patients, yet accounts for a disproportionately higher rate of BC morbidity and mortality, in part due to lack of targeted therapies. Using well-validated antibodies, Estrogen Receptor Beta (ERβ) protein has been shown to be expressed in approximately 25% of TNBCs and is associated with improved patient outcomes. Using multiple ERβ +/- TNBC cell lines and PDX models, we have demonstrated that ligand-mediated activation of ERβ by estradiol (E2) decreases cell proliferation, invasion, and migration in vitro, as well as primary tumor growth and metastatic spread in vivo.
Methods: To determine the mechanisms by which ERβ elicits these anti-cancer effects, we elucidated the ERβ transcriptome and cistrome via Microarray and ChIPseq, respectively, in TNBC cells stably expressing ERβ in a doxycycline-inducible manner. We also performed gene expression and luciferase assays to assess the impact of ERβ on NFκB signaling, followed by ChIP-PCR and ChIPseq to assess how ERβ modifies chromatin architecture near NFκB target genes.
Results: Pathway analysis of ERβ-regulated genes identified NFκB signaling as one of the most suppressed pathways in response to E2 treatment. Indeed, numerous NFκB target genes were among the most down-regulated genes following E2 treatment but only in the presence of ERβ expression. Chromatin Immunoprecipitation followed by sequencing (ChIPseq) revealed that ERβ primarily associated with estrogen response elements (EREs), but was also enriched around NFκB binding sites following E2 treatment. In fact, 12% of all ERβ binding sites were enriched for NFκB response elements and ERβ was shown to physically associate with NFκB protein. Using an NFκB reporter construct and qPCR, ERβ was shown to block TNFα-mediated induction of NFκB signaling and NFκB target gene expression. Globally, RNAseq identified 200 genes to be significantly regulated by TNFα in TNBC cells, of which 81 were significantly altered in the presence of E2+TNFα. ChIPseq demonstrated that ligand-mediated activation of ERβ significantly diminished an activating histone mark (H3K27Ac) at many of these NFκB target genes while enhancing a repressive mark (H3K27Me3). These modifications are also associated with recruitment of the histone methyltransferase, EZH2, to enhancer elements of these NFκB target genes. Drug-mediated blockade of HDAC and EZH2 activity reversed suppression of NFκB target gene expression by ERβ.
Conclusions: Our data suggest that ERβ may elicit its anti-cancer effects in part via formation of a novel co-repressor complex consisting of ERβ, NFκB, and EZH2. These data are in keeping with prior observations of the importance of NFκB signaling as it relates to TNBC cell proliferation and invasion, and that decreased expression of NFκB target genes is associated with improved outcomes in TNBC patients. Currently, a Mayo Breast SPORE prospective study is underway to investigate the role of estradiol in ERβ expressing TNBC and to further evaluate the cross-talk between ERβ and NFκB signaling in TNBC.
Citation Format: Aspros K, Nelson A, Ye Z, Sun Z, Chernukhin I, Carroll J, Ingle J, Goetz M, Hawse J. Estrogen receptor beta elicits anti-cancer effects in triple negative breast cancer through suppression of NFκB signaling [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-05-03.
Collapse
Affiliation(s)
- K Aspros
- Mayo Clinic, Rochester, MN; Cambridge Research Institute, Cambridge, United Kingdom
| | - A Nelson
- Mayo Clinic, Rochester, MN; Cambridge Research Institute, Cambridge, United Kingdom
| | - Z Ye
- Mayo Clinic, Rochester, MN; Cambridge Research Institute, Cambridge, United Kingdom
| | - Z Sun
- Mayo Clinic, Rochester, MN; Cambridge Research Institute, Cambridge, United Kingdom
| | - I Chernukhin
- Mayo Clinic, Rochester, MN; Cambridge Research Institute, Cambridge, United Kingdom
| | - J Carroll
- Mayo Clinic, Rochester, MN; Cambridge Research Institute, Cambridge, United Kingdom
| | - J Ingle
- Mayo Clinic, Rochester, MN; Cambridge Research Institute, Cambridge, United Kingdom
| | - M Goetz
- Mayo Clinic, Rochester, MN; Cambridge Research Institute, Cambridge, United Kingdom
| | - J Hawse
- Mayo Clinic, Rochester, MN; Cambridge Research Institute, Cambridge, United Kingdom
| |
Collapse
|
2
|
Cairns J, Ingle J, Dudenkov T, Kalari K, Buzdar A, Kubo M, Robson M, Ellis M, Goss P, Shepherd L, Goetz M, Weinshilboum R, Wang L. Abstract PD1-04: CSMD1 SNPs selectively affect anastrozole response in postmenopausal breast cancer patients. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-pd1-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND: Based on prospective clinical trials, there is no evidence for differences in efficacy between the 3 aromatase inhibitors (AIs) anastrozole, exemestane, and letrozole. The purpose of this study was to identify germline genetic variants associated with response to AIs and to help identify novel mechanisms associated with drug disease efficacy.
METHODS: A genome-wide association study (GWAS) was performed for 624 patients (Steroids 2015;99:32-38) to identify SNPs associated with estrogen level change in women with estrogen receptor (ER) positive breast cancer treated with anastrozole. Replication of associated SNPs was performed in a GWAS from the MA.27 trial that compared adjuvant anastrozole and exemestane treatment of post-menopausal women with ER+ breast cancer. Functional studies were subsequently performed to determine SNP effects and underlying mechanisms.
RESULTS: Our initial GWAS identified SNPs within CSMD1 that were associated with changes in estrogen levels during anastrozole therapy. An additional SNP in CSMD1 was also associated with breast cancer events in CCTG MA.27. Functionally, we showed that CSMD1 regulates CYP19 expression in a SNP-, and in an anastrozole- dependent fashion. These phenomena were not observed for either letrozole or exemestane. In MA.27, an anastrozole- specific effect was also seen with the minor allele having a protective effect on time to distant metastasis (HR=0.49, p=0.00259), but this was not the case for exemestane (HR=0.71, p=0.111). Our in vitro functional studies indicated that overexpression of CSMD1 sensitized anastrozole or letrozole resistant cells to anastrozole but not to the other two AIs. The SNP in CSMD1 that was associated with increased CSMD1 and CYP19 expression levels increased anastrozole sensitivity, but not letrozole or exemestane in lymphoblastoid cell lines (LCLs) homozygous for either WT or variant CSMD1 SNP genotypes. Based on these observations, we explored whether anastrozole has additional mechanisms beyond its function as a CYP19 inhibitor. Utilizing an estrogen response element (ERE) luciferase reporter assay in a CYP19 CRISPR knockout breast cancer T47D cell line and a surface plasmon resonance (SPR) assay, we found that anastrozole can also function as an ERα agonist, and can bind to, and result in, proteasome dependent ERα degradation, especially in the presence of E2. Treatment of these CYP19 CRISPR knockout cells with anastrozole in the presence of increasing concentrations of E2 results in greater sensitivity compared with anastrozole alone, while the addition of E2, as expected, does not improve letrozole or exemestane sensitivity. These same observations were also seen in letrozole and anastrazole resistant cells.
CONCLUSIONS: Our findings suggest that anastrozole might be more effective than letrozole or exemestane in patients with the CSMD1 SNP. Furthermore, anastrozole can function as an ERα agonist, binding to ERα and resulting in its degradation, especially in the presence of E2. These findings should help to make it possible to develop precision endocrine therapies for women who are candidates for AIs.
Citation Format: Cairns J, Ingle J, Dudenkov T, Kalari K, Buzdar A, Kubo M, Robson M, Ellis M, Goss P, Shepherd L, Goetz M, Weinshilboum R, Wang L. CSMD1 SNPs selectively affect anastrozole response in postmenopausal breast cancer patients [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr PD1-04.
Collapse
Affiliation(s)
- J Cairns
- Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; Riken Center for Integrative Medical Science, Yokohama, Japan; Memorial Sloan Kettering Cancer Center, New York, NY; Baylor Cancer Center, Houston, TX; Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Kingston, ON, Canada
| | - J Ingle
- Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; Riken Center for Integrative Medical Science, Yokohama, Japan; Memorial Sloan Kettering Cancer Center, New York, NY; Baylor Cancer Center, Houston, TX; Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Kingston, ON, Canada
| | - T Dudenkov
- Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; Riken Center for Integrative Medical Science, Yokohama, Japan; Memorial Sloan Kettering Cancer Center, New York, NY; Baylor Cancer Center, Houston, TX; Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Kingston, ON, Canada
| | - K Kalari
- Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; Riken Center for Integrative Medical Science, Yokohama, Japan; Memorial Sloan Kettering Cancer Center, New York, NY; Baylor Cancer Center, Houston, TX; Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Kingston, ON, Canada
| | - A Buzdar
- Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; Riken Center for Integrative Medical Science, Yokohama, Japan; Memorial Sloan Kettering Cancer Center, New York, NY; Baylor Cancer Center, Houston, TX; Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Kingston, ON, Canada
| | - M Kubo
- Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; Riken Center for Integrative Medical Science, Yokohama, Japan; Memorial Sloan Kettering Cancer Center, New York, NY; Baylor Cancer Center, Houston, TX; Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Kingston, ON, Canada
| | - M Robson
- Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; Riken Center for Integrative Medical Science, Yokohama, Japan; Memorial Sloan Kettering Cancer Center, New York, NY; Baylor Cancer Center, Houston, TX; Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Kingston, ON, Canada
| | - M Ellis
- Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; Riken Center for Integrative Medical Science, Yokohama, Japan; Memorial Sloan Kettering Cancer Center, New York, NY; Baylor Cancer Center, Houston, TX; Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Kingston, ON, Canada
| | - P Goss
- Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; Riken Center for Integrative Medical Science, Yokohama, Japan; Memorial Sloan Kettering Cancer Center, New York, NY; Baylor Cancer Center, Houston, TX; Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Kingston, ON, Canada
| | - L Shepherd
- Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; Riken Center for Integrative Medical Science, Yokohama, Japan; Memorial Sloan Kettering Cancer Center, New York, NY; Baylor Cancer Center, Houston, TX; Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Kingston, ON, Canada
| | - M Goetz
- Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; Riken Center for Integrative Medical Science, Yokohama, Japan; Memorial Sloan Kettering Cancer Center, New York, NY; Baylor Cancer Center, Houston, TX; Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Kingston, ON, Canada
| | - R Weinshilboum
- Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; Riken Center for Integrative Medical Science, Yokohama, Japan; Memorial Sloan Kettering Cancer Center, New York, NY; Baylor Cancer Center, Houston, TX; Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Kingston, ON, Canada
| | - L Wang
- Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; Riken Center for Integrative Medical Science, Yokohama, Japan; Memorial Sloan Kettering Cancer Center, New York, NY; Baylor Cancer Center, Houston, TX; Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Kingston, ON, Canada
| |
Collapse
|
3
|
Reese J, Bruinsma E, Subramaniam M, Suman V, Pitel K, Kalari K, Yu J, Wang L, Goetz M, Ingle J, Hawse J. Abstract P5-04-01: ERβ elicits tumor suppressive effects in triple negative breast cancer through the induction of cystatins and suppression of TGFβ signaling. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p5-04-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Triple negative breast cancer (TNBC) accounts for approximately 20% of all breast cancer diagnoses. Clinical management of TNBC is limited to surgery, chemotherapy and radiation due to lack of estrogen receptor alpha and HER2 expression. Recently, we have shown that approximately 40% of TNBCs express estrogen receptor beta (ERβ) and have begun to explore the possibility that this receptor could be utilized as a novel therapeutic target for this disease.
Methods: To examine the biological functions of ERβ in TNBC, novel ERβ expressing TN cell lines (MDA-MB-231 and Hs578T) were developed. In vitro experiments were employed to determine alterations in the global gene expression profiles, biological pathways, proliferation rates, and cell cycle progression following estrogen or ERβ-specific agonist treatment. Cell line xenografts were also established in athymic ovariectomized nude mice to examine tumoral responses to ERβ targeting agents and to investigate gene and protein expression patterns as well as potential serum biomarkers indicative of therapeutic response. Additionally, using the resources of the Mayo Clinic Breast Cancer Genome Guided Therapy Study (BEAUTY), we have identified, and begun to analyze, ERβ+ and ERβ- patient derived xenografts (PDX) established from women with TNBC.
Results: Our studies have revealed that both estrogen and multiple ERβ-specific agonists elicit significant anti-proliferative effects in ERβ+ TNBC cells primarily through a G1/S phase cell cycle arrest. These anti-proliferative effects appear to be mediated by cystatins, a family of small secreted cysteine protease inhibitors which are highly induced following estrogen and ERβ-specific agonist treatment. Conditioned media isolated from estrogen or ERβ-specific agonist treated cells decreased the proliferation rates of multiple non-ERβ expressing cell lines; effects that were completely reversed when cystatins were depleted from the media. In addition, we have shown that activation of ERβ, and the subsequent induction of cystatin gene expression, leads to suppression of canonical TGFβ signaling through multiple mechanisms including suppression of TGFβR2 expression, induction of Smad7 expression and blockade of TGFβ ligand-mediated activation of this pathway both in vitro and in vivo. Finally, ERβ+ TNBC PDXs exhibit significantly decreased tumor growth rates in estrogen-treated mice compared to ERβ- TN breast tumors.
Conclusions: Our in vitro and in vivo data show that estrogen and ERβ-specific agonists elicit anti-cancer effects in ERβ+ TNBC. These effects appear to be mediated, in part, by cystatins through their inhibitory effects on canonical TGFB signaling, a pathway known to drive TNBC progression. Importantly, these data lay the foundation for studies aimed at examining the ability to therapeutically target ERβ in TNBC patients.
Citation Format: Reese J, Bruinsma E, Subramaniam M, Suman V, Pitel K, Kalari K, Yu J, Wang L, Goetz M, Ingle J, Hawse J. ERβ elicits tumor suppressive effects in triple negative breast cancer through the induction of cystatins and suppression of TGFβ signaling. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P5-04-01.
Collapse
Affiliation(s)
| | | | | | | | | | | | - J Yu
- Mayo Clinic, Rochester, MN
| | - L Wang
- Mayo Clinic, Rochester, MN
| | | | | | | |
Collapse
|
4
|
Palermo A, Ingle J, Moore L, Willow B, Cohen M, Cahalin L. Comparison of inspiratory performance in division 1 collegiate athletes using the Test of Incremental Respiratory Endurance (TIRE). Physiotherapy 2015. [DOI: 10.1016/j.physio.2015.03.356] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
5
|
Gucalp A, Tolaney S, Isakoff SJ, Ingle J, Liu MC, Carey L, Blackwell KL, Rugo H, Nabell L, Forero A, Stearns V, Momen L, Gonzalez J, Akhtar A, Giri DD, Patil S, Feigin KN, Hudis CA, Traina TA. Abstract P6-05-02: Endocrine biomarkers in response to AR-inhibition with bicalutamide for the treatment of AR(+), ER/PR(−) metastatic breast cancer (MBC) (TBCRC011). Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p6-05-02] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Our group and others have identified a subset of ER/PR(−) breast cancers characterized by expression of the androgen receptor (AR) and androgen-dependent growth (Doane 2006). We conducted a proof-of-concept multicenter phase II study to test the efficacy of the AR-antagonist, bicalutamide for the treatment of AR(+) ER/PR(−) MBC (NCT00468715). Results of the primary endpoint, clinical benefit rate (CBR), were presented at ASCO (Gucalp 2012). Data for the impact of bicalutamide on circulating hormone levels in women are limited. Elevations in serum testosterone (T) and estradiol (E) have been observed for men treated with bicalutamide. We hypothesized comparable patterns of change in circulating endocrine markers in response to bicalutamide for women with MBC.
Methods: Patients (pts) with AR(+) (IHC ≥10%), ER/PR(−) (IHC <10%) MBC were eligible for treatment (tx) if ECOG performance status ≤2 and normal organ function regardless of menopausal status. There was no limit to prior tx except prior trastuzumab required if HER2(+). Tx consisted of bicalutamide 150mg orally daily in 28-day cycles (C). Toxicity assessed q4 weeks, response q12wks. Primary endpoint was CBR. Peripheral blood was collected for total and free T, E and sex hormone binding globulin (SHBG) at baseline, start of C2 (C2) and at end of study (EOS). Standard institutional assays were used. A Wilcoxon signed-rank test was done to compare baseline to C2 and EOS values.
Results: 26 patients with AR(+) ER/PR(−) MBC were treated on study. Evaluable number (n) of pts at baseline, C2 and EOS are 26, 26 and 19 respectively. Two pts remain on study. Menopausal status: pre=2, post=24. Baseline median total and free T and estradiol were consistent with expected norms, however a wide range was observed (Table). There were no significant differences observed for median free T, total T, E or SHBG between baseline and C2 or baseline and EOS. Changes in hormone levels could not be stratified by menopausal status or response to bicalutamide given small sample size. Given the wide range of baseline values, we examined the percent change for each endocrine biomarker from baseline to C2 and EOS. As shown in the Table, there was no difference in median percent change observed across time points for each biomarker.
Conclusions: No discernible patterns of change in T, E or SHBG were observed in response to bicalutamide therapy when given to women for the treatment of AR(+), ER/PR(−) MBC. These circulating hormones require further evaluation for use as a pharmacodynamic marker.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P6-05-02.
Collapse
Affiliation(s)
- A Gucalp
- Memorial Sloan-Kettering Cancer Center; Dana Farber/Harvard Cancer Center; Mayo Clinic Cancer Center; Lombardi Comprehensive Cancer Center at Georgetown University; University of North Carolina Lineberger Cancer Center; University of California San Francisco Comprehensive Cancer Center; Duke University Medical Cancer Center; University of Alabama Comprehensive Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
| | - S Tolaney
- Memorial Sloan-Kettering Cancer Center; Dana Farber/Harvard Cancer Center; Mayo Clinic Cancer Center; Lombardi Comprehensive Cancer Center at Georgetown University; University of North Carolina Lineberger Cancer Center; University of California San Francisco Comprehensive Cancer Center; Duke University Medical Cancer Center; University of Alabama Comprehensive Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
| | - SJ Isakoff
- Memorial Sloan-Kettering Cancer Center; Dana Farber/Harvard Cancer Center; Mayo Clinic Cancer Center; Lombardi Comprehensive Cancer Center at Georgetown University; University of North Carolina Lineberger Cancer Center; University of California San Francisco Comprehensive Cancer Center; Duke University Medical Cancer Center; University of Alabama Comprehensive Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
| | - J Ingle
- Memorial Sloan-Kettering Cancer Center; Dana Farber/Harvard Cancer Center; Mayo Clinic Cancer Center; Lombardi Comprehensive Cancer Center at Georgetown University; University of North Carolina Lineberger Cancer Center; University of California San Francisco Comprehensive Cancer Center; Duke University Medical Cancer Center; University of Alabama Comprehensive Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
| | - MC Liu
- Memorial Sloan-Kettering Cancer Center; Dana Farber/Harvard Cancer Center; Mayo Clinic Cancer Center; Lombardi Comprehensive Cancer Center at Georgetown University; University of North Carolina Lineberger Cancer Center; University of California San Francisco Comprehensive Cancer Center; Duke University Medical Cancer Center; University of Alabama Comprehensive Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
| | - L Carey
- Memorial Sloan-Kettering Cancer Center; Dana Farber/Harvard Cancer Center; Mayo Clinic Cancer Center; Lombardi Comprehensive Cancer Center at Georgetown University; University of North Carolina Lineberger Cancer Center; University of California San Francisco Comprehensive Cancer Center; Duke University Medical Cancer Center; University of Alabama Comprehensive Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
| | - KL Blackwell
- Memorial Sloan-Kettering Cancer Center; Dana Farber/Harvard Cancer Center; Mayo Clinic Cancer Center; Lombardi Comprehensive Cancer Center at Georgetown University; University of North Carolina Lineberger Cancer Center; University of California San Francisco Comprehensive Cancer Center; Duke University Medical Cancer Center; University of Alabama Comprehensive Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
| | - H Rugo
- Memorial Sloan-Kettering Cancer Center; Dana Farber/Harvard Cancer Center; Mayo Clinic Cancer Center; Lombardi Comprehensive Cancer Center at Georgetown University; University of North Carolina Lineberger Cancer Center; University of California San Francisco Comprehensive Cancer Center; Duke University Medical Cancer Center; University of Alabama Comprehensive Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
| | - L Nabell
- Memorial Sloan-Kettering Cancer Center; Dana Farber/Harvard Cancer Center; Mayo Clinic Cancer Center; Lombardi Comprehensive Cancer Center at Georgetown University; University of North Carolina Lineberger Cancer Center; University of California San Francisco Comprehensive Cancer Center; Duke University Medical Cancer Center; University of Alabama Comprehensive Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
| | - A Forero
- Memorial Sloan-Kettering Cancer Center; Dana Farber/Harvard Cancer Center; Mayo Clinic Cancer Center; Lombardi Comprehensive Cancer Center at Georgetown University; University of North Carolina Lineberger Cancer Center; University of California San Francisco Comprehensive Cancer Center; Duke University Medical Cancer Center; University of Alabama Comprehensive Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
| | - V Stearns
- Memorial Sloan-Kettering Cancer Center; Dana Farber/Harvard Cancer Center; Mayo Clinic Cancer Center; Lombardi Comprehensive Cancer Center at Georgetown University; University of North Carolina Lineberger Cancer Center; University of California San Francisco Comprehensive Cancer Center; Duke University Medical Cancer Center; University of Alabama Comprehensive Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
| | - L Momen
- Memorial Sloan-Kettering Cancer Center; Dana Farber/Harvard Cancer Center; Mayo Clinic Cancer Center; Lombardi Comprehensive Cancer Center at Georgetown University; University of North Carolina Lineberger Cancer Center; University of California San Francisco Comprehensive Cancer Center; Duke University Medical Cancer Center; University of Alabama Comprehensive Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
| | - J Gonzalez
- Memorial Sloan-Kettering Cancer Center; Dana Farber/Harvard Cancer Center; Mayo Clinic Cancer Center; Lombardi Comprehensive Cancer Center at Georgetown University; University of North Carolina Lineberger Cancer Center; University of California San Francisco Comprehensive Cancer Center; Duke University Medical Cancer Center; University of Alabama Comprehensive Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
| | - A Akhtar
- Memorial Sloan-Kettering Cancer Center; Dana Farber/Harvard Cancer Center; Mayo Clinic Cancer Center; Lombardi Comprehensive Cancer Center at Georgetown University; University of North Carolina Lineberger Cancer Center; University of California San Francisco Comprehensive Cancer Center; Duke University Medical Cancer Center; University of Alabama Comprehensive Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
| | - DD Giri
- Memorial Sloan-Kettering Cancer Center; Dana Farber/Harvard Cancer Center; Mayo Clinic Cancer Center; Lombardi Comprehensive Cancer Center at Georgetown University; University of North Carolina Lineberger Cancer Center; University of California San Francisco Comprehensive Cancer Center; Duke University Medical Cancer Center; University of Alabama Comprehensive Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
| | - S Patil
- Memorial Sloan-Kettering Cancer Center; Dana Farber/Harvard Cancer Center; Mayo Clinic Cancer Center; Lombardi Comprehensive Cancer Center at Georgetown University; University of North Carolina Lineberger Cancer Center; University of California San Francisco Comprehensive Cancer Center; Duke University Medical Cancer Center; University of Alabama Comprehensive Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
| | - KN Feigin
- Memorial Sloan-Kettering Cancer Center; Dana Farber/Harvard Cancer Center; Mayo Clinic Cancer Center; Lombardi Comprehensive Cancer Center at Georgetown University; University of North Carolina Lineberger Cancer Center; University of California San Francisco Comprehensive Cancer Center; Duke University Medical Cancer Center; University of Alabama Comprehensive Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
| | - CA Hudis
- Memorial Sloan-Kettering Cancer Center; Dana Farber/Harvard Cancer Center; Mayo Clinic Cancer Center; Lombardi Comprehensive Cancer Center at Georgetown University; University of North Carolina Lineberger Cancer Center; University of California San Francisco Comprehensive Cancer Center; Duke University Medical Cancer Center; University of Alabama Comprehensive Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
| | - TA Traina
- Memorial Sloan-Kettering Cancer Center; Dana Farber/Harvard Cancer Center; Mayo Clinic Cancer Center; Lombardi Comprehensive Cancer Center at Georgetown University; University of North Carolina Lineberger Cancer Center; University of California San Francisco Comprehensive Cancer Center; Duke University Medical Cancer Center; University of Alabama Comprehensive Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
| |
Collapse
|
6
|
Ingle J. Pharmacogenetics /Genomics (PGX) to Optimize Endocrine Therapy. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)32631-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
7
|
Ligibel J, Cirrincione C, Citron M, Ingle J, Gradishar W, Martino S, Hudis C, Winer E, Berry D. 413 Relationship Between Body Mass Index (BMI) and Outcomes in Node-positive Breast Cancer Patients Receiving Chemotherapy–Results From CALGB/Intergroup 9741. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)70479-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
8
|
Goetz M, Hou X, Suman V, Reinicke K, Kuffel M, Haluska P, Oberg A, Grill D, Reid J, Brodie A, Ingle J, Ames M. PD01-06: Endoxifen Exhibits Potent Anti-Tumor Activity and Regulates Different Genes Than Tamoxifen in an Aromatase Expressing MCF7 Model Resistant to Letrozole. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-pd01-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: First in human studies of Z-endoxifen hydrochloride (E), the active metabolite of tamoxifen (T), are underway in metastatic breast cancer (BC). Previous data have demonstrated the superiority of aromatase inhibitors (AI's) over T in estrogen receptor (ER) + BC. Using an in vivo aromatase expressing model (MCF7/AC1), we compared the antitumor activity of E with T and Letrozole (L), as well as the antitumor activity and global gene expression changes of E with T in an L-resistant model.
Methods: MCF7/AC1 tumors were stimulated with androstenedione. Once tumor size reached 300 mm3, mice (30/group) were randomly assigned to one of five treatment groups: control (daily, po), T (500 μg/day, sc), endoxifen 25 mg/kg/day p.o.(LDE) endoxifen 75 mg/kg/day p.o. (HDE) or letrozole, 10 μg/day s.c for 4 weeks. Tumors were harvested from control, T, and E groups while the L group continued treatment until the development of resistance defined as an increase in tumor volume of at least 300% from day 1. Mice with L-resistant tumors were randomly assigned to T (n=4) or E (n=5) for 4 weeks and then sacrificed. Gene expression in L-resistant tumors was quantified using Affymetrix U133+2 and changes in gene expression profiles [comparing T and E with L-resistant (n=3)] were analyzed. Genes identified as significantly different were confirmed by real-time RT-PCR assays.
Results: At the 4 week time point, both doses of E and L resulted in greater anti-tumor activity than control (Wilcoxon rank sum test: all p < 0.0001); however, tumor burden did not differ between T and control (p=0.095). HDE resulted in significantly less tumor burden than T (p=0.002) but was similar to L. In mice that continued on L, resistance developed at 24 weeks in 9/25 mice. These mice were randomly assigned to either T (n=4) or E (n=5) for 4 weeks. Tumor volume (expressed as a% of its size prior to randomization) was significantly different comparing E (73.3%; range: 69.3 to 80.75%) versus T (148.39%; range: 114.07 to 165.99%) (Wilcoxon rank sum test p=0.016). Compared to control, microarray studies identified 1518 unique probe sets regulated by E (p<0.001) compared to 441 for T including estrogen-regulated genes such as progesterone receptor (PGR) and amphiregulin (AREG) that were significantly down-regulated in the E group [PGR (−6.2 fold, p=0.000008) and AREG (−3.2 fold, p=.0006) but unchanged or up-regulated in the T group (PGR unchanged and AREG +9.2 fold p=0.00002). These findings were confirmed by RT-PCR.
Conclusions: Using the MCF7/AC1 model previously used to show the superiority of AI's over T, HDE demonstrated similar antitumor activity to L and was superior to T. In cells resistant to L, E was superior to T and gene expression changes demonstrate that E down-regulates while T activates estrogen regulated genes. These findings support the ongoing development of E for the treatment of ER+ BC.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr PD01-06.
Collapse
Affiliation(s)
- M Goetz
- 1Mayo Clinic, Rochester, MN; University of Maryland, Baltimore, MD
| | - X Hou
- 1Mayo Clinic, Rochester, MN; University of Maryland, Baltimore, MD
| | - V Suman
- 1Mayo Clinic, Rochester, MN; University of Maryland, Baltimore, MD
| | - K Reinicke
- 1Mayo Clinic, Rochester, MN; University of Maryland, Baltimore, MD
| | - M Kuffel
- 1Mayo Clinic, Rochester, MN; University of Maryland, Baltimore, MD
| | - P Haluska
- 1Mayo Clinic, Rochester, MN; University of Maryland, Baltimore, MD
| | - A Oberg
- 1Mayo Clinic, Rochester, MN; University of Maryland, Baltimore, MD
| | - D Grill
- 1Mayo Clinic, Rochester, MN; University of Maryland, Baltimore, MD
| | - J Reid
- 1Mayo Clinic, Rochester, MN; University of Maryland, Baltimore, MD
| | - A Brodie
- 1Mayo Clinic, Rochester, MN; University of Maryland, Baltimore, MD
| | - J Ingle
- 1Mayo Clinic, Rochester, MN; University of Maryland, Baltimore, MD
| | - M Ames
- 1Mayo Clinic, Rochester, MN; University of Maryland, Baltimore, MD
| |
Collapse
|
9
|
Vachon CM, Brandt KR, Suman VJ, Weinshilboum R, Kosel ML, Wu F, Serie DJ, Olson JE, Buzdar AU, Shepherd LE, Goss PE, Ingle JN. Abstract P2-09-03: Mammographic Density Response to Aromatase Inhibitor Therapy. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p2-09-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Mammographic density, the variation in fat, epithelial and stromal tissues seen on screening mammography, is a strong risk factor for breast cancer and can be modified by hormonal agents. Changes in density from tamoxifen or postmenopausal hormone (PMH) use are associated with risk, suggesting that density may be a surrogate marker of therapeutic efficacy. Aromatase inhibitors (AIs) are given as adjuvant therapy in hormone receptor positive postmenopausal breast cancer and are known to decrease levels of estrone and estradiol in both serum and breast tissue. Our goal here was to examine the influence of AIs on mammographic density in women with early breast cancer.
Methods: We conducted a case-control study of postmenopausal breast cancer patients initiating adjuvant AI therapy (anastrozole or exemestane) on protocols NCIC CTG MA27, NCCTG N063I and MC (Mayo Clinic) 0532. Eligibility included; an intact contralateral breast with no prior surgery; a screening mammogram within twelve months before AI initiation and at 9-15 months on therapy; no prior endocrine therapy and informed consent. Controls were sampled from the Mayo Mammography Health Study, a cohort of 19,924 receiving screening mammography at the Mayo Clinic, and matched to cases on age, prior PMH use, baseline body mass index (BMI) and interval between mammograms. Pre-treatment and on-study mammograms for cases (corresponding mammograms for controls) were digitized. Change in percent density was estimated on the craniocaudal view of the non-cancerous breast using two methods: a subjective assessment of change by an expert radiologist (within 5%; 5-10% increase, 10-25% increase, 25%+ increase, 5-10% decrease, 10-25% decrease and 25%+ decrease) and a quantitative assessment of absolute change using a computer-assisted thresholding program (Cumulus). Analyses compared magnitude of change in density by both the subjective and quantitative methods between cases and matched controls. Results: 574 pairs were eligible for analyses (MA27-505 cases; N063I-12 cases; MC0532-57 cases). Characteristics of the two groups are shown in the table below. Using either density estimation method, there was a greater decrease in density among women on AI therapy vs. matched controls. In 33% (95% CI: 29-37%) of pairs, there was at least a one greater category decrease for the case relative to her control by subjective estimation. In 14% (95% CI: 11-18%) of the pairs, there was at least a 5% greater decrease for the case relative to her control by quantitative estimation. Data will be available according to AI class (non-steroidal versus steroidal) in November.
Conclusions: In the largest report to date to examine the influence of AI therapy on mammographic density, we provide evidence that AI is associated with decreases in density in a small subgroup of women. We are currently examining factors that influence these AI-associated decreases in density and whether these differences are unique to one class of AI. (Supported in part by NIH grants P50CA116201, U01GM61388, U10CA77202, U10CA25224)
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P2-09-03.
Collapse
Affiliation(s)
- CM Vachon
- Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX; National Cancer Institute of Canada Clinical Trials Group, Kingston, ON, Canada; Massachusetts General Hospital, Boston, MA
| | - KR Brandt
- Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX; National Cancer Institute of Canada Clinical Trials Group, Kingston, ON, Canada; Massachusetts General Hospital, Boston, MA
| | - VJ Suman
- Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX; National Cancer Institute of Canada Clinical Trials Group, Kingston, ON, Canada; Massachusetts General Hospital, Boston, MA
| | - R Weinshilboum
- Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX; National Cancer Institute of Canada Clinical Trials Group, Kingston, ON, Canada; Massachusetts General Hospital, Boston, MA
| | - ML Kosel
- Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX; National Cancer Institute of Canada Clinical Trials Group, Kingston, ON, Canada; Massachusetts General Hospital, Boston, MA
| | - F Wu
- Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX; National Cancer Institute of Canada Clinical Trials Group, Kingston, ON, Canada; Massachusetts General Hospital, Boston, MA
| | - DJ Serie
- Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX; National Cancer Institute of Canada Clinical Trials Group, Kingston, ON, Canada; Massachusetts General Hospital, Boston, MA
| | - JE Olson
- Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX; National Cancer Institute of Canada Clinical Trials Group, Kingston, ON, Canada; Massachusetts General Hospital, Boston, MA
| | - AU Buzdar
- Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX; National Cancer Institute of Canada Clinical Trials Group, Kingston, ON, Canada; Massachusetts General Hospital, Boston, MA
| | - LE Shepherd
- Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX; National Cancer Institute of Canada Clinical Trials Group, Kingston, ON, Canada; Massachusetts General Hospital, Boston, MA
| | - PE Goss
- Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX; National Cancer Institute of Canada Clinical Trials Group, Kingston, ON, Canada; Massachusetts General Hospital, Boston, MA
| | - JN. Ingle
- Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX; National Cancer Institute of Canada Clinical Trials Group, Kingston, ON, Canada; Massachusetts General Hospital, Boston, MA
| |
Collapse
|
10
|
Abstract
1. Possible mechanisms regulating the activities of three enzymes involved in nitrate assimilation, nitrate reductase, nitrite reductase and glutamate dehydrogenase, were studied in radish cotyledons. 2. Nitrate-reductase and nitrite-reductase activities are low in nitrogen-deficient cotyledons, and are induced by their substrates. 3. Glutamate dehydrogenase is present regardless of the nitrogen status, and the enzyme can be increased only slightly by long-term growth on ammonia. 4. Although nitrate is the best inducer of nitrate reductase, lower levels of induction are also obtained with nitrite and ammonia. The experiments did not distinguish between direct or indirect induction by these two molecules. 5. Nitrite reductase is induced by nitrite and only indirectly by nitrate. 6. The induction of both nitrate reductase and nitrite reductase is prevented by the inhibitors actinomycin D, puromycin and cycloheximide, indicating a requirement for the synthesis of RNA and protein. 7. The decay of nitrate reductase, determined after inhibition of protein synthesis, is slower than the synthesis of the enzyme. Nitrite reductase is much more stable than nitrate reductase. 8. The synthesis of nitrate reductase is not repressed by ammonia, but is repressed by growth on a nitrite medium. 9. There is no inhibition of nitrate reductase, nitrite reductase or glutamate dehydrogenase by the normal end products of assimilation, but cyanate is a fairly specific inhibitor of nitrate reductase.
Collapse
Affiliation(s)
- J Ingle
- Department of Botany, Purdue University, Lafayette, Ind., U.S.A
| |
Collapse
|
11
|
Gendler S, Pathangey L, Lakshminarayanan V, Mukherjee P, Pockaj B, Suman V, Loserth L, Markovic S, Ingle J. Examination of Immune Competence in Breast Cancer Patients at Six Months Post Surgery and Adjuvant Therapy through Assessment of T Cell and Dendritic Cell Functionality. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-4131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
It has long been known that immune suppression is induced by the presence of a tumor, resulting in compromised T cell and dendritic cell (DC) functionality. What is not well understood is how soon the immune system recovers normal functionality following surgical removal of tumors and adjuvant therapy. This timing is of critical importance, as the effectiveness of therapeutic immune strategies relies on optimal presentation of antigens and activation of T cells. Blood from breast cancer patients was collected prior to surgery and at 3 and 6 months post adjuvant therapy. Patients were treated with surgery (breast conservation or mastectomy) and chemotherapy (CT) (n=22) or surgery without chemotherapy (n=38). Most patients had radiation therapy (RT). Blood from 22 healthy woman of similar age served as controls. T cell functionality (TCF) was determined following stimulation with plate-bound anti-CD3 (1 µg/ml) and anti-CD28 (0.5 µg/ml) and proliferation was measured by 3H-thymidine uptake. DC functionality (DCF) was determined by ability to present allo-antigens in a mixed lymphocyte reaction. Values for the normal samples determined the normal ranges (NR). Responses were grouped into 4 categories based on their status at 6 months: Group 1 - remained in NR; Group 2 - climbed into NR; Group 3 - remained below NR; Group 4 - fell below NR. Analysis of immunosuppression will be based on lymphocyte subsets, cytokine, COX-2, and PGE2 metabolite levels.T Cell Proliferation AllWith CTNo CT N=60N=22N=38Group 120%14%24%Group 223%23%24%Group 338%41%37%Group 418%23%16% DC Function AllWith CTNo CT N=58N=20N=38Group 143%35%47%Group 219%25%16%Group 317%15%18%Group 421%25%18% Forty-three percent of patients had normal levels (Groups 1 and 2) for TCF and 62% for DCF by 6 months post adjuvant therapy, suggesting that breast cancer patients are potentially amenable to vaccine therapy. 28% of patients had both TCF and DCF in NR; 50% had either TCF or DCF in NR; and 22% had neither in NR. The percentage of patients who had TCF in NR by adjuvant therapy was: 35% CT+RT (6/17); 33% CT (1/3); 52% (17/33) RT; and 20% (1/5) neither. The percentage of patients who had DCF in NR by adjuvant therapy was: 67% (10/15) CT+RT; 33% (1/3) CT; 67% (22/33) RT; and 40% (2/5) neither. Proper understanding of the effects of tumor, chemotherapy and radiation therapy on immune function, especially the effects on T cells and DCs, may enable us to identify the appropriate patients in whom to study immunotherapy approaches in women with early breast cancer and to examine strategies to counteract cancer-related defects in immune function. (supported by P50CA116201)
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 4131.
Collapse
|
12
|
Ingle J, Schaid D, Goss P, Mushiroda T, Chapman J, Kubo M, Jenkins G, Batzler A, Liu M, Shepherd L, Ellis M, Flockhart D, Nakamura Y, Weinshilboum R. A Genome-Wide Association Study in Patients Experiencing Musculoskeletal Adverse Events on Aromatase Inhibitors as Adjuvant Therapy in Early Breast Cancer Entered on NCIC CTG Trial MA.27. A Pharmacogenetics Research Network-RIKEN Collaboration. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-15] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The third-generation aromatase inhibitors (AIs) are established adjuvant therapy for postmenopausal women with early stage breast cancer. Musculoskeletal adverse events (MS AE) have become increasingly recognized as an issue for many women receiving AIs resulting in decreased quality of life and, in some instances, discontinuation of the AI. MA.27 is an ongoing randomized clinical trial comparing anastrozole with exemestane that accrued 7576 patients (pts), including 6827 from North America, about 79% of whom provided DNA and consent for genetic testing. A review of withdrawals related to adverse events revealed that the most common cause was MS AE. The hypothesis for our study was that a genome-wide association (GWA) case control study would identify single nucleotide polymorphisms (SNPs) associated with MS AE.Methods: Cases were defined as pts with grade 3 or 4 MS AE (NCI CTCAE v3.0) or who went off treatment for any grade MS AE within the first 2 years and were matched to 2 controls based on treatment arm, length of follow-up, prior chemotherapy, age and prior celecoxib (at least 3 months prior to MS AE). The study was restricted to the 94% of pts self-identified as Caucasian. Genotyping was performed with the Illumina Human610-Quad. Genotype quality control prior to analysis required call rates ≥98%. Eigenstrat analyses were performed to control for population stratification.Results: The GWA study included 293 cases and 586 controls with 6 pts (0.7%) (4 cases, 2 controls) excluded for call rates <98%. 551,358 SNPs were used in the analyses after removing 29,439 for a minor allele frequency <1% and 82 with Hardy Weinberg Equilibrium p-values <10-6. Eigenvectors did not impact the results when used as covariates. Four SNPs with the lowest p-values (3.3-8.2 x 10-6, Armitage test), 3 in high LD (r2>.8) on chromosome (ch) 14 (rs7158782, rs7159713, rs2369049) and 1 on the X ch (rs6637820) were identified. The gene closest (4000-7000 bp) to the 3 SNPs on ch 14 was T-Cell Leukemia 1A (TCL1A), encoding a protein known to augment AKT kinase activity. Expression array data from lymphoblastoid cell lines from 300 subjects of 3 ethnicities revealed that all 3 SNPs were associated with decreased TCL1A expression after adjusting for ethnicity using 2 probe sets (p=0.006 to 0.03). Electromobility shift assay (EMSA) showed that 2 of these SNPs (rs7158782, rs7159713) displayed a shift and the former SNP showed substantially less binding for variant than wild type. The gene closest to the X ch SNP was Immunoglobulin Superfamily 1 (IGSF1), but EMSA did not show a shift for this SNP.Conclusions: MS AEs represent a major impediment to optimal use of AIs in women with breast cancer and this GWA study identified SNPs on ch 14 that provide a focus for further research to identify pts at risk for, and means to ameliorate, this adverse event.(Supported in part by NIH grants U01GM61388, U01GM63173, P50CA116201 and U10CA77202)
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 15.
Collapse
Affiliation(s)
| | | | | | | | | | - M. Kubo
- 3RIKEN Center for Genomic Medicine, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Goetz M, Reinicke K, Reid J, Suman V, Kuffel M, Safgren S, Buhrow S, Reynolds C, Jenkins R, Hawse J, Perez E, Ingle J, Ames M. Tamoxifen, HER2, and Endoxifen: The Role of CYP2D6 as a Predictor of Tamoxifen Resistance in ER+/HER2+ Breast Cancer. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-2006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Endoxifen, the active metabolite of tamoxifen (Tam), is currently being developed as a drug for the treatment of estrogen receptor (ER) + breast cancer (BC). HER2 expression in ER+ BC is associated with Tam resistance, and in vivo Tam administration to mice bearing ER+/HER2+ xenografts stimulates BC growth (Shou, JNCI 2004). In humans, endoxifen is the most important Tam metabolite responsible for inhibiting estrogen induced BC growth (Wu, Cancer Research 2009). CYP2D6 metabolism affects the concentrations (conc) of endoxifen (Stearns, JNCI, 2003) and associated with worse disease free survival (DFS) in Tam treated BC (Goetz, JCO, 2005). We sought to determine the activity of Tam and its metabolites in ER+/HER2+ BC cell lines and to evaluate the role of CYP2D6 metabolism in Tam-treated patients (pts) with ER+/HER2+ BC. Additionally, we sought to determine endoxifen conc in mice administered oral Tam.Methods: MCF7 (parental and HER2-expressing) and BT474 (ER+/HER2+) cells were used to compare the activity of Tam, 4HT, and endoxifen on estrogen- stimulated growth. Oral tam PK were characterized in mice treated with standard dose of Tam (4 mg/kg; 100 μg). Clinical data were obtained via a retrospective analysis of Tam-treated pts with ER+/ HER2+ BC randomized to receive 5 years of Tam (NCCTG 89-30-52). CYP2D6 metabolism (extensive or decreased) was based on CYP2D6 genotype (*3, 4, 6, 10, 17, 41) and co-administration of a CYP2D6 inhibitor (yes/no). HER2 was determined by immunohistochemistry (IHC) or FISH (tumors 0, 1, or 2+ by IHC). The association between CYP2D6 and DFS was assessed using the log-rank test and proportional hazards modeling.Results: Compared to Tam, endoxifen potently inhibited the growth of estrogen- stimulated BT474 cells. In MCF7 cells, expression of HER2 shifted the conc of endoxifen required for 50% inhibition of growth (IC50) from 54 nM (parental) to 131 nM (HER2 expressing). Using the range of conc of Tam and its metabolites observed in humans (Tam, 300-500 nM; 4HT, 5-10 nM; and endoxifen, 10-200 nM), only endoxifen potently inhibited estrogen- stimulated growth of MCF7HER2+ cells and only at conc achievable in CYP2D6 extensive metabolizers (>50nM). In mice, conc of 4HT and endoxifen were below 15 nM following an oral dose of 4 mg/kg. In NCCTG 89-30-52, both CYP2D6 phenotype and HER2 status was determined in 201/256 randomized pts. HER2 was expressed in 23/215 (11%) but not associated with DFS overall (p=0.62). In the HER2+ subset, pts with decreased CYP2D6 metabolism (n=10) had significantly shorter DFS compared to extensive metabolizers (n=9) (HR 9.5, p=0.03; 95% CI 1.16-76.9).Conclusions: Our in vitro and clinical data provide a simple pharmacological model for understanding HER2 resistance in Tam-treated breast cancer. Mice, which lack the CYP2D6 enzyme, may not be an appropriate model for understanding tam resistance given low conc of both 4HT and endoxifen. Given that the in vitro conc of endoxifen needed to inhibit the growth of ER+/HER-2+ BC are achievable in only a subset of humans (CYP2D6 extensive metabolizers), the primary administration of endoxifen could overcome de novo Tam resistance in ER+/HER2+ BC.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 2006.
Collapse
|
14
|
McKean HA, Reynolds C, Hoskin TL, Suman VJ, Grant CS, Erlander MG, Ma X, Ingle J, Goetz MP. Ductal carcinoma in situ of the breast and gene expression markers for prediction of invasive recurrence. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.550] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
550 Background: Ductal carcinoma in situ (DCIS) is a heterogeneous group of non-invasive cancers with varying propensity for recurrence. There are no validated markers that identify patients at risk for invasive recurrence following lumpectomy. HOXB13/IL17BR (H/I) is expressed in both DCIS and invasive cancer (Ma Cancer Cell. 2004) and associated with recurrence in stage I cancer. A 5-gene molecular grade index (MGI) distinguishes outcome in grade II disease (Ma Clin Cancer Res. 2008). We sought to determine whether H/I or MGI was associated with invasive recurrence in resected DCIS. Methods: We identified patients at Mayo Rochester who underwent lumpectomy ± radiation for DCIS between 1988 and 2001 and performed a nested case/control study. Cases were patients with ipsilateral invasive recurrence, matched to controls based on age, surgery date, length of follow-up, and adjuvant radiation. DCIS was macrodissected from paraffin sections and RNA extracted to obtain H/I and MGI RT-PCR profiles. The association of H/I and MGI with case-control status was assessed with conditional logistic regression; results reported are odds ratios (OR) with 95% confidence intervals (CI). The association of H/I and MGI as continuous variables with nuclear grade (low, intermediate, high) was estimated with Spearman's rank correlation. Results: 427 patients underwent lumpectomy for DCIS, and 33 were identified as possible cases. Histologic review excluded 8 (non-sufficient tissue or DCIS recurrence without invasion). 25 cases were matched to 48 controls (2 controls for 23 cases, 1 control for 2 cases). Both H/I (r = 0.43, p = 0.0001) and MGI (r = 0.41, p = 0.0004) were significantly correlated with nuclear grade. Positive H/I was associated with trend towards higher recurrence (OR 1.9; p = 0.22) that was most pronounced in cases/controls (15/28) treated with lumpectomy alone (OR 3.3; CI: 0.8–13.2, p = 0.09). Similarly, positive MGI was associated with a trend towards higher recurrence risk in patients treated with surgery alone (OR 2.0; CI: 0.6–6.4, p = 0.27). Conclusions: These data suggest that both HOXB13/IL17BR and MGI can identify a subset of patients with surgically resected DCIS who are at risk for invasive recurrence. Further studies in larger cohorts are needed to confirm these findings. [Table: see text]
Collapse
Affiliation(s)
- H. A. McKean
- Mayo Clinic College of Medicine, Rochester, MN; bioTheranostics, San Diego, CA
| | - C. Reynolds
- Mayo Clinic College of Medicine, Rochester, MN; bioTheranostics, San Diego, CA
| | - T. L. Hoskin
- Mayo Clinic College of Medicine, Rochester, MN; bioTheranostics, San Diego, CA
| | - V. J. Suman
- Mayo Clinic College of Medicine, Rochester, MN; bioTheranostics, San Diego, CA
| | - C. S. Grant
- Mayo Clinic College of Medicine, Rochester, MN; bioTheranostics, San Diego, CA
| | - M. G. Erlander
- Mayo Clinic College of Medicine, Rochester, MN; bioTheranostics, San Diego, CA
| | - X. Ma
- Mayo Clinic College of Medicine, Rochester, MN; bioTheranostics, San Diego, CA
| | - J. Ingle
- Mayo Clinic College of Medicine, Rochester, MN; bioTheranostics, San Diego, CA
| | - M. P. Goetz
- Mayo Clinic College of Medicine, Rochester, MN; bioTheranostics, San Diego, CA
| |
Collapse
|
15
|
Buzdar A, Tan-Chiu E, Schwartzberg L, Perez A, Ellis M, Garin A, Ingle J, Carlson R. A multi-center phase II study of three doses of TAS-108 in postmenopausal women with advanced breast carcinoma following first or second line endocrine therapy. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-2131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #2131
Introduction: TAS-108 is an oral steroidal anti-estrogen agent that selectively inhibits ERα and is mainly metabolized by CYP3A4. The purpose of this study is to investigate the efficacy and safety of TAS-108 administrated orally in three dose levels in patients with locally advanced, locally recurrent inoperable or metastatic breast carcinoma (BC) in four countries (USA, Russia, Mexico and Chile).
 Methods: Postmenopausal women with confirmed ER and/or PgR positive BC who had previously responded to one or two standard endocrine therapies, with or without one prior chemotherapy were randomly assigned to three doses of TAS-108, 40 mg, 80 and 120 mg daily. Using a modified Panageas' optimal two-stage trinomial design, the enrollment of 60 evaluable patients (first-stage: 19) was required to each individual dose group. Tumor response was assessed every 8 weeks according to RECIST criteria. Adverse events (AEs) were graded by CTC-AE v3.0.
 Results: A total of 146 patients with mean age of 63 years old were enrolled with 61 patients in the 40 mg group and 66 in the 80 mg group. The 120 mg group was terminated at the end of stage 1 with 19 patients enrolled due to lack of efficacy. The mean duration of study treatment was 172 days for the 40 mg group and 160 days for the 80 mg group. Partial response (PR) was documented in 6 (10%) patients in the 40 mg group and 4 (6.7%) patients in the 80 mg group. The rate of disease stabilization (CR+PR+SD) reported by the investigators was 43% (95%CI, 31%,56%) in the 40 mg group and 45% (95%CI, 32%,58%) in the 80 mg group. Adjudicated clinical benefit (CR+PR+SD more than 24 wks) was observed in 22% of patients in the 40 mg group and 20% of patients in the 80 mg group. Clinical benefit was achieved in 25% of patients with 1 prior hormonal therapy and 15% of patients with more than one line of prior hormonal therapy. Median time to progression (TTP): 15 weeks for the 40 mg group and 15.9 weeks for the 80 mg group. Median duration of clinical benefit was 32 weeks in the 40 mg group and 64 weeks in the 80 mg group. In the 40/80/120 mg groups, the commonly reported treatment-related AEs included nausea (15%/11%/16%), fatigue (10%/11%/16%), headache (10%/6%/16%), hot flushes (10%/5%/32%), diarrhea (2%/6%/5%), constipation (3%/3%/5%), and arthralgia (2%/5%/11%). No endometrial cancer and treatment-related deaths occurred during the study.
 Conclusions: TAS-108 has demonstrated anti-tumor activity in this population and was generally well tolerated. The 40 mg dose was chosen as the recommended dose for future clinical evaluation in patients with advanced breast cancer.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 2131.
Collapse
Affiliation(s)
- A Buzdar
- 1 MD Anderson Cancer Center, Houston, TX
| | - E Tan-Chiu
- 2 Florida Cancer Research Institute, Davie, FL
| | | | - A Perez
- 4 Memorial Regional Hospital, Hollywood, FL
| | - M Ellis
- 5 Washington University, St. Louis, MO
| | - A Garin
- 6 Russian Cancer Research Institute, Moscow, Russian Federation
| | - J Ingle
- 7 Mayo Clinic, Rochester, MN
| | - R Carlson
- 8 Stanford Cancer Center, Stanford, CA
| |
Collapse
|
16
|
Vachon C, Sasano H, Ghosh K, Brandt K, Santen R, Watson D, Lingle W, Goss P, Hartmann L, Reynolds C, Pankratz VS, Ingle J. Evaluation of aromatase expression in mammographically dense and non-dense regions of the breast in healthy women. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-4033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #4033
Background: Aromatase activity within the breast is a source of estrogen that may cause breast cancer. Mammographic density (MD) is a risk factor for breast cancer whose biologic basis is unknown. Our study compared aromatase expression in tissue from dense and non-dense areas of the breasts of healthy volunteers.
 Methods: Participants were 40+ yrs, had a screening mammogram with visible MD, no history of cancer and were not on endocrine therapy. Ultrasound-guided core biopsies were done within 6 months of mammography to obtain three paired cores from mammographically dense and non-dense regions of the breast. Immunostaining for aromatase expression employed the streptavidin-biotin amplification method using the recently developed 677 mouse monoclonal antibody. Immunoreactivity (IR) was scored in terms of proportion of cells staining positive for aromatase (PPC) (0=<1%, 1=1-25%, 2=26-50%, 3=51+% (and 4=75%+ for adipocytes)) and relative immunointensity (0=none, 1=weak, 2=moderate, 3=intense) for each cell type (stroma, normal ductal epithelium, adipocytes). A composite score weighting the PPC by their relative intensity (range 0-9; 0-12 for adipocytes) was also calculated. The sum of the composite score across the three cell types provided a global assessment of aromatase IR. Repeated measures analyses evaluated differences in aromatase IR for dense compared to non-dense tissue within and across cell types. Parameter estimates (β) indicated the average difference between dense and non-dense IR.
 Results: 18 (37%) of the 49 participants were premenopausal (median age 46 yrs). Summing across cell types, the global composite score showed increased aromatase IR on sections sampled from dense vs. non-dense regions (β=5.3,p<0.001). This global difference reflected increased aromatase IR in the stroma and normal ductal epithelium from dense sections (vs. non-dense). For 42 women with >1% stromal cells on each section, there was evidence for increased IR on dense sections as indicated by the greater PPCs (β=0.9), relative intensity (β=0.7) and composite score (β=2.7)(p's<0.001). Similarly, for 20 women with >1% normal ductal epithelium in both dense and non-dense sections, there was a greater composite score (β=1.4,p=0.004) for cells on dense sections although differences for PPC (β=0.3,p=0.11) and relative intensity (β=0.3,p=0.09) did not reach statistical significance. No differences were seen in IR for adipocytes from the two density regions (46 women). Findings were unchanged with adjustment for covariates, including proportions of each cell type per section.
 Conclusions: There is strong evidence for increased aromatase expression in the stromal and normal ductal epithelium of dense vs. non-dense tissue. These results support ongoing research into mammographic density as a biomarker of effect of aromatase inhibitors.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 4033.
Collapse
Affiliation(s)
| | - H Sasano
- 2 Tohoku University School of Medicine, Tohoku, Japan
| | - K Ghosh
- 1 Mayo Clinic, Rochester, MN
| | | | - R Santen
- 3 University of Virginia, Virginia
| | | | | | - P Goss
- 4 Massachusetts General Hospital, Boston
| | | | | | | | - J Ingle
- 1 Mayo Clinic, Rochester, MN
| |
Collapse
|
17
|
Geyer C, Mamounas E, Jeong JH, Wickerham L, Ganz P, Hutchins L, Eisen A, Ingle J, Costantino J, Wolmark N. P117 Exemestane (EXE) as extended adjuvant therapy after 5 years of tamoxifen (TAM): results of NSABP B-33. Breast 2007. [DOI: 10.1016/s0960-9776(07)70177-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
18
|
Hayes DF, Thor A, Dressler L, Weaver D, Broadwater G, Goldstein L, Martino S, Ingle J, Henderson IC, Berry D. HER2 predicts benefit from adjuvant paclitaxel after AC in node-positive breast cancer: CALGB 9344. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.510] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
510 Background: CALGB 9344 showed 4 cycles of paclitaxel (T) after 4 cycles of doxorubicin/cyclophosphamide (AC) improved disease-free (DFS) and overall survival (OS) compared to 4 cycles of AC. Higher dose of A had no benefit (Henderson JCO ’03). Prior studies suggest HER2 is associated with benefit from standard vs low dose of C&A (Dressler JCO ’05). We hypothesized that HER2 might predict benefit from higher dose of A or from T, and that HER2 might refine the observed negative interaction of T with estrogen receptor (ER). Methods: 3121 node + women in CALGB 9344 received 4 q3wk cycles of AC (A: 60, 75, or 90 mg/m2) and then 4 cycles of T (175 mg/m2 q3wk) or no T. Blocks were collected from ∼2800 subjects. 2 sets of 750 patients each were randomly selected from these cases: Set 1 to develop hypotheses; Set 2 for validation. Tissue specimens were available from 643 (set1) and 679 (set2) cases (20% & 22% total enrolled in 9344 respectively). HER2 was evaluated by FISH and by IHC (by antibody cb11 and by Herceptest). Statistical analyses used Cox proportional hazards models, including interaction terms, and Kaplan-Meier estimates for comparing 5-yr DFS by treatment group. Results: In Set 1, all 3 assays suggested that T improved DFS for HER2+ but not for HER2-. For this single set the interaction was not statistically significant. There appeared to be an interaction of HER2, T and ER. IHC using cb11 was applied to Set 2, revealing nearly identical results. In the two sets combined (n=1322), the interaction between HER2 and T was statistically significant (p=0.013). The 3-way interaction of HER2, ER and T was hypothesis-generating and not tested statistically. Differences in 5-yr DFS rates (95% CI) for T vs. no T by HER2 and ER (both sets combined) There was no interaction between HER2 and dose of A. Conclusions: These results suggest that the benefit of adding T to AC is greater for HER2+ tumors, even if ER+, while T was of no apparent benefit in the ER+, HER2- group. Further validation is needed from remaining cases in 9344 and from other trials involving T. [Table: see text] [Table: see text]
Collapse
Affiliation(s)
- D. F. Hayes
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Oklahoma Health Sciences Center, Oklahoma City, OK; University of North Carolina, Chapel Hill, NC; University of Vermont, Burlington, VT; Duke University, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Cancer Institute Medical Group, Santa Monica, CA; Mayo Clinic, Rochester, MN; University of California San Francisco, San Francisco, CA; M. D. Anderson Cancer Center, Houston, TX
| | - A. Thor
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Oklahoma Health Sciences Center, Oklahoma City, OK; University of North Carolina, Chapel Hill, NC; University of Vermont, Burlington, VT; Duke University, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Cancer Institute Medical Group, Santa Monica, CA; Mayo Clinic, Rochester, MN; University of California San Francisco, San Francisco, CA; M. D. Anderson Cancer Center, Houston, TX
| | - L. Dressler
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Oklahoma Health Sciences Center, Oklahoma City, OK; University of North Carolina, Chapel Hill, NC; University of Vermont, Burlington, VT; Duke University, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Cancer Institute Medical Group, Santa Monica, CA; Mayo Clinic, Rochester, MN; University of California San Francisco, San Francisco, CA; M. D. Anderson Cancer Center, Houston, TX
| | - D. Weaver
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Oklahoma Health Sciences Center, Oklahoma City, OK; University of North Carolina, Chapel Hill, NC; University of Vermont, Burlington, VT; Duke University, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Cancer Institute Medical Group, Santa Monica, CA; Mayo Clinic, Rochester, MN; University of California San Francisco, San Francisco, CA; M. D. Anderson Cancer Center, Houston, TX
| | - G. Broadwater
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Oklahoma Health Sciences Center, Oklahoma City, OK; University of North Carolina, Chapel Hill, NC; University of Vermont, Burlington, VT; Duke University, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Cancer Institute Medical Group, Santa Monica, CA; Mayo Clinic, Rochester, MN; University of California San Francisco, San Francisco, CA; M. D. Anderson Cancer Center, Houston, TX
| | - L. Goldstein
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Oklahoma Health Sciences Center, Oklahoma City, OK; University of North Carolina, Chapel Hill, NC; University of Vermont, Burlington, VT; Duke University, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Cancer Institute Medical Group, Santa Monica, CA; Mayo Clinic, Rochester, MN; University of California San Francisco, San Francisco, CA; M. D. Anderson Cancer Center, Houston, TX
| | - S. Martino
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Oklahoma Health Sciences Center, Oklahoma City, OK; University of North Carolina, Chapel Hill, NC; University of Vermont, Burlington, VT; Duke University, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Cancer Institute Medical Group, Santa Monica, CA; Mayo Clinic, Rochester, MN; University of California San Francisco, San Francisco, CA; M. D. Anderson Cancer Center, Houston, TX
| | - J. Ingle
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Oklahoma Health Sciences Center, Oklahoma City, OK; University of North Carolina, Chapel Hill, NC; University of Vermont, Burlington, VT; Duke University, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Cancer Institute Medical Group, Santa Monica, CA; Mayo Clinic, Rochester, MN; University of California San Francisco, San Francisco, CA; M. D. Anderson Cancer Center, Houston, TX
| | - I. C. Henderson
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Oklahoma Health Sciences Center, Oklahoma City, OK; University of North Carolina, Chapel Hill, NC; University of Vermont, Burlington, VT; Duke University, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Cancer Institute Medical Group, Santa Monica, CA; Mayo Clinic, Rochester, MN; University of California San Francisco, San Francisco, CA; M. D. Anderson Cancer Center, Houston, TX
| | - D. Berry
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Oklahoma Health Sciences Center, Oklahoma City, OK; University of North Carolina, Chapel Hill, NC; University of Vermont, Burlington, VT; Duke University, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Cancer Institute Medical Group, Santa Monica, CA; Mayo Clinic, Rochester, MN; University of California San Francisco, San Francisco, CA; M. D. Anderson Cancer Center, Houston, TX
| |
Collapse
|
19
|
Ingle J, Tu D, Shepherd L, Palmer M, Pater J, Goss P. NCIC CTG MA.17: Intent to treat analysis (ITT) of randomized patients after a median follow-up of 54 months. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.549] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
549 Background: MA.17 evaluated letrozole (LET) or placebo (PLAC) after 5 years of tamoxifen (Tam) and showed [median follow-up 30 months (mos)] significant improvement in disease-free survival (DFS) for LET [hazard ratio (HR) 0.57, p = 0.00008]. The trial was unblinded and PLAC patients (pts) were offered LET. An ITT analysis of all outcomes, before and after unblinding, based on the original randomization was performed. Methods: A stratified log-rank test was used to compare DFS, distant (D)DFS, overall survival (OS) and incidence of contra-lateral breast cancer (CBC). The Cox regression model used baseline stratification variables and two prespecified factors, menopausal status at the start of Tam and time on Tam. Subgroup analyses for DFS and OS were performed for the two prespecified subsets. All p-values were two-sided Results: 5187 pts were randomized at baseline and, at unblinding, 1655 of 2268 PLAC pts accepted LET. At median follow-up of 54 mos (range,16–86) 363 recurrences or CBC’s (144 LET and 219 PLAC) occurred; 118 LET and 176 PLAC pts had recurrent disease and 26 LET and 43 PLAC pts had CBC. 4 year DFS was 94.3% (LET) and 91.4% (PLAC) (HR 0.64; 95% CI, 0.52 - 0.79; p = 0.00002). Corresponding 4 year DDFS was 96.2% and 94.9% (HR 0.76; 0.58–0.99; p = 0.041). 4 year OS was 95.0% (LET) and 95.1% (PLAC) (HR 1.00; 0.78–1.28; p = 0.99). LET was equally effective in node +ve and -ve pts (i.e., similar HRs) in DFS. OS was not significantly different for LET and PLAC in any subgroup. The annual rate of CBC was 0.29% LET (0.18–0.40) and 0.47% PLAC (0.34–0.61); HR 0.61 (0.38–0.98) p = 0.037. 255 pts had died as of the data cut-off (128 LET and 127 PLAC). Conclusions: In this ITT analysis, pts originally randomized to LET within 3 months of stopping Tam did better than PLAC pts in DFS, DDFS and CBC, despite 73% of PLAC pts crossing to LET after unblinding. This highlights the strong beneficial effect of extended adjuvant therapy with LET. [Table: see text]
Collapse
Affiliation(s)
- J. Ingle
- Mayo Clinic, Rochester, MN; National Cancer Institute Canada Clinical Trials Group, Kingston, ON, Canada; Massachusetts General Hospital Cancer Center, Boston, MA
| | - D. Tu
- Mayo Clinic, Rochester, MN; National Cancer Institute Canada Clinical Trials Group, Kingston, ON, Canada; Massachusetts General Hospital Cancer Center, Boston, MA
| | - L. Shepherd
- Mayo Clinic, Rochester, MN; National Cancer Institute Canada Clinical Trials Group, Kingston, ON, Canada; Massachusetts General Hospital Cancer Center, Boston, MA
| | - M. Palmer
- Mayo Clinic, Rochester, MN; National Cancer Institute Canada Clinical Trials Group, Kingston, ON, Canada; Massachusetts General Hospital Cancer Center, Boston, MA
| | - J. Pater
- Mayo Clinic, Rochester, MN; National Cancer Institute Canada Clinical Trials Group, Kingston, ON, Canada; Massachusetts General Hospital Cancer Center, Boston, MA
| | - P. Goss
- Mayo Clinic, Rochester, MN; National Cancer Institute Canada Clinical Trials Group, Kingston, ON, Canada; Massachusetts General Hospital Cancer Center, Boston, MA
| |
Collapse
|
20
|
Affiliation(s)
- J L Key
- DEPARTMENT OF BOTANY AND PLANT PATHOLOGY, PURDUE UNIVERSITY
| | | |
Collapse
|
21
|
Bearman SI, Green S, Gralow J, Barlow W, Hudis C, Wolff A, Ingle J, Hortobagyi G, Livingston R, Martino S. SWOG/Intergroup 9623: A phase III comparison of intensive sequential chemotherapy to high dose chemotherapy and autologous hematopoietic progenitor cell support (AHPCS) for primary breast cancer in women with ≥4 involved axillary lymph nodes. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.572] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- S. I. Bearman
- Rocky Mtn Cancer Ctr, Denver, CO; Southwest Oncology Group, Seattle, WA; Univ Washington, Seattle, WA; Memorial Sloan-Kettering Cancer Ctr and CALGB, New York, NY; Johns Hopkins and ECOG, Baltimore, MD; Mayo Clinic and NCCTG, Rochester, MN; MD Anderson, Houston, TX; Cancer Inst Med Group, Santa Monica, CA
| | - S. Green
- Rocky Mtn Cancer Ctr, Denver, CO; Southwest Oncology Group, Seattle, WA; Univ Washington, Seattle, WA; Memorial Sloan-Kettering Cancer Ctr and CALGB, New York, NY; Johns Hopkins and ECOG, Baltimore, MD; Mayo Clinic and NCCTG, Rochester, MN; MD Anderson, Houston, TX; Cancer Inst Med Group, Santa Monica, CA
| | - J. Gralow
- Rocky Mtn Cancer Ctr, Denver, CO; Southwest Oncology Group, Seattle, WA; Univ Washington, Seattle, WA; Memorial Sloan-Kettering Cancer Ctr and CALGB, New York, NY; Johns Hopkins and ECOG, Baltimore, MD; Mayo Clinic and NCCTG, Rochester, MN; MD Anderson, Houston, TX; Cancer Inst Med Group, Santa Monica, CA
| | - W. Barlow
- Rocky Mtn Cancer Ctr, Denver, CO; Southwest Oncology Group, Seattle, WA; Univ Washington, Seattle, WA; Memorial Sloan-Kettering Cancer Ctr and CALGB, New York, NY; Johns Hopkins and ECOG, Baltimore, MD; Mayo Clinic and NCCTG, Rochester, MN; MD Anderson, Houston, TX; Cancer Inst Med Group, Santa Monica, CA
| | - C. Hudis
- Rocky Mtn Cancer Ctr, Denver, CO; Southwest Oncology Group, Seattle, WA; Univ Washington, Seattle, WA; Memorial Sloan-Kettering Cancer Ctr and CALGB, New York, NY; Johns Hopkins and ECOG, Baltimore, MD; Mayo Clinic and NCCTG, Rochester, MN; MD Anderson, Houston, TX; Cancer Inst Med Group, Santa Monica, CA
| | - A. Wolff
- Rocky Mtn Cancer Ctr, Denver, CO; Southwest Oncology Group, Seattle, WA; Univ Washington, Seattle, WA; Memorial Sloan-Kettering Cancer Ctr and CALGB, New York, NY; Johns Hopkins and ECOG, Baltimore, MD; Mayo Clinic and NCCTG, Rochester, MN; MD Anderson, Houston, TX; Cancer Inst Med Group, Santa Monica, CA
| | - J. Ingle
- Rocky Mtn Cancer Ctr, Denver, CO; Southwest Oncology Group, Seattle, WA; Univ Washington, Seattle, WA; Memorial Sloan-Kettering Cancer Ctr and CALGB, New York, NY; Johns Hopkins and ECOG, Baltimore, MD; Mayo Clinic and NCCTG, Rochester, MN; MD Anderson, Houston, TX; Cancer Inst Med Group, Santa Monica, CA
| | - G. Hortobagyi
- Rocky Mtn Cancer Ctr, Denver, CO; Southwest Oncology Group, Seattle, WA; Univ Washington, Seattle, WA; Memorial Sloan-Kettering Cancer Ctr and CALGB, New York, NY; Johns Hopkins and ECOG, Baltimore, MD; Mayo Clinic and NCCTG, Rochester, MN; MD Anderson, Houston, TX; Cancer Inst Med Group, Santa Monica, CA
| | - R. Livingston
- Rocky Mtn Cancer Ctr, Denver, CO; Southwest Oncology Group, Seattle, WA; Univ Washington, Seattle, WA; Memorial Sloan-Kettering Cancer Ctr and CALGB, New York, NY; Johns Hopkins and ECOG, Baltimore, MD; Mayo Clinic and NCCTG, Rochester, MN; MD Anderson, Houston, TX; Cancer Inst Med Group, Santa Monica, CA
| | - S. Martino
- Rocky Mtn Cancer Ctr, Denver, CO; Southwest Oncology Group, Seattle, WA; Univ Washington, Seattle, WA; Memorial Sloan-Kettering Cancer Ctr and CALGB, New York, NY; Johns Hopkins and ECOG, Baltimore, MD; Mayo Clinic and NCCTG, Rochester, MN; MD Anderson, Houston, TX; Cancer Inst Med Group, Santa Monica, CA
| |
Collapse
|
22
|
Whelan T, Goss P, Ingle J, Pater J, Shepherd L, Palmer M, Tu D, Robert N, Martino S, Muss H. Assessment of quality of life (QOL) in MA.17, a randomized placebo-controlled trial of letrozole in postmenopausal women following five years of tamoxifen. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.517] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- T. Whelan
- McMaster University, Hamilton, ON, Canada; Princess Margaret Hospital, Toronto, ON, Canada; Mayo Clinic, Rochester, MN; Toronto Sunnybrook Regional Cancer Centre, Toronto, ON, Canada; National Cancer Institute of Canada, CTG, Kingston, ON, Canada; Inova Fairfax Hospital, Falls Church, VA; John Wayne Cancer Institute, Santa Monica, CA; University of Vermont, Burlington, VT
| | - P. Goss
- McMaster University, Hamilton, ON, Canada; Princess Margaret Hospital, Toronto, ON, Canada; Mayo Clinic, Rochester, MN; Toronto Sunnybrook Regional Cancer Centre, Toronto, ON, Canada; National Cancer Institute of Canada, CTG, Kingston, ON, Canada; Inova Fairfax Hospital, Falls Church, VA; John Wayne Cancer Institute, Santa Monica, CA; University of Vermont, Burlington, VT
| | - J. Ingle
- McMaster University, Hamilton, ON, Canada; Princess Margaret Hospital, Toronto, ON, Canada; Mayo Clinic, Rochester, MN; Toronto Sunnybrook Regional Cancer Centre, Toronto, ON, Canada; National Cancer Institute of Canada, CTG, Kingston, ON, Canada; Inova Fairfax Hospital, Falls Church, VA; John Wayne Cancer Institute, Santa Monica, CA; University of Vermont, Burlington, VT
| | - J. Pater
- McMaster University, Hamilton, ON, Canada; Princess Margaret Hospital, Toronto, ON, Canada; Mayo Clinic, Rochester, MN; Toronto Sunnybrook Regional Cancer Centre, Toronto, ON, Canada; National Cancer Institute of Canada, CTG, Kingston, ON, Canada; Inova Fairfax Hospital, Falls Church, VA; John Wayne Cancer Institute, Santa Monica, CA; University of Vermont, Burlington, VT
| | - L. Shepherd
- McMaster University, Hamilton, ON, Canada; Princess Margaret Hospital, Toronto, ON, Canada; Mayo Clinic, Rochester, MN; Toronto Sunnybrook Regional Cancer Centre, Toronto, ON, Canada; National Cancer Institute of Canada, CTG, Kingston, ON, Canada; Inova Fairfax Hospital, Falls Church, VA; John Wayne Cancer Institute, Santa Monica, CA; University of Vermont, Burlington, VT
| | - M. Palmer
- McMaster University, Hamilton, ON, Canada; Princess Margaret Hospital, Toronto, ON, Canada; Mayo Clinic, Rochester, MN; Toronto Sunnybrook Regional Cancer Centre, Toronto, ON, Canada; National Cancer Institute of Canada, CTG, Kingston, ON, Canada; Inova Fairfax Hospital, Falls Church, VA; John Wayne Cancer Institute, Santa Monica, CA; University of Vermont, Burlington, VT
| | - D. Tu
- McMaster University, Hamilton, ON, Canada; Princess Margaret Hospital, Toronto, ON, Canada; Mayo Clinic, Rochester, MN; Toronto Sunnybrook Regional Cancer Centre, Toronto, ON, Canada; National Cancer Institute of Canada, CTG, Kingston, ON, Canada; Inova Fairfax Hospital, Falls Church, VA; John Wayne Cancer Institute, Santa Monica, CA; University of Vermont, Burlington, VT
| | - N. Robert
- McMaster University, Hamilton, ON, Canada; Princess Margaret Hospital, Toronto, ON, Canada; Mayo Clinic, Rochester, MN; Toronto Sunnybrook Regional Cancer Centre, Toronto, ON, Canada; National Cancer Institute of Canada, CTG, Kingston, ON, Canada; Inova Fairfax Hospital, Falls Church, VA; John Wayne Cancer Institute, Santa Monica, CA; University of Vermont, Burlington, VT
| | - S. Martino
- McMaster University, Hamilton, ON, Canada; Princess Margaret Hospital, Toronto, ON, Canada; Mayo Clinic, Rochester, MN; Toronto Sunnybrook Regional Cancer Centre, Toronto, ON, Canada; National Cancer Institute of Canada, CTG, Kingston, ON, Canada; Inova Fairfax Hospital, Falls Church, VA; John Wayne Cancer Institute, Santa Monica, CA; University of Vermont, Burlington, VT
| | - H. Muss
- McMaster University, Hamilton, ON, Canada; Princess Margaret Hospital, Toronto, ON, Canada; Mayo Clinic, Rochester, MN; Toronto Sunnybrook Regional Cancer Centre, Toronto, ON, Canada; National Cancer Institute of Canada, CTG, Kingston, ON, Canada; Inova Fairfax Hospital, Falls Church, VA; John Wayne Cancer Institute, Santa Monica, CA; University of Vermont, Burlington, VT
| |
Collapse
|
23
|
Abstract
We describe three unusual cases of suicide involving multiple gunshot wounds, in which all of the victims suffered gunshot wounds to the head, yet none was rendered immediately incapacitated. Injuries were confined to the same area in two of the cases and were located in different areas in the other case. Two of the cases initially appeared to be homicides rather than suicides.
Collapse
Affiliation(s)
- A Sekula-Perlman
- Office of the Chief Medical Examiner, State of Delaware, Wilmington 19801, USA
| | | | | | | | | |
Collapse
|
24
|
Abstract
This prospective randomised trial compared the performance of three dressing protocols in the management of 36 dehisced surgical abdominal wounds: a standard alginate; a gauze moistened with sodium hypochlorite (0.05%); and a combine dressing pad. Outcomes assessed were: healing time (cm2 per day and cm3 per day), patient comfort (pain and satisfaction) and cost. There were no statistically significant differences in healing rates between the three groups but there was a trend for the combine dressing pad protocol to produce a greater reduction in wound area. The combine dressing pad protocol performed well when compared with the calcium alginate in terms of healing time, patient comfort and cost. Maximum pain was significantly greater (p = 0.011) and satisfaction significantly lower among patients who received the sodium hypochlorite protocol. Costs during the in-patient phase were also substantially higher for the sodium hypochlorite protocol. Trial results support the view that sodium hypochlorite dressing protocols for surgical wounds should be abandoned.
Collapse
Affiliation(s)
- M Cannavo
- St George Hospital, Kogarah, Australia
| | | | | | | | | |
Collapse
|
25
|
Abstract
Surveys of exposure to inhalable dust have been carried out in two woodworking machine shops and five other woodworking shops where both manual and machine tool work is carried out. The Occupational Exposure Limits for wood dust were found to be frequently exceeded in some workshops. It is possible that the fraction of dust projected from woodworking machines towards the operator may have contributed both to measured dust concentrations and to exposure. Dust exposure may be reduced by careful attention to enclosure and ventilation, possibly using total enclosure at some machines. Emission of dust from portable orbital type sanding machines was considerably reduced by the use of low-volume high-velocity type extraction. It is suggested that suppliers of woodworking machines should provide data on dust emission to assist the user to manage better the introduction of new machines.
Collapse
Affiliation(s)
- A Hamill
- Occupational Health and Safety Service, Sydney Hospital, NSW, Australia
| | | | | | | |
Collapse
|
26
|
Begg CB, Zelen M, Carbone PP, McFadden ET, Brodovsky H, Engstrom P, Hatfield A, Ingle J, Schwartz B, Stolbach L. Cooperative groups and community hospitals. Measurement of impact in the community hospitals. Cancer 1983; 52:1760-7. [PMID: 6616426 DOI: 10.1002/1097-0142(19831101)52:9<1760::aid-cncr2820520934>3.0.co;2-r] [Citation(s) in RCA: 35] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
The Eastern Cooperative Oncology Group, composed of major cancer treatment centers, has an outreach program which involves community hospitals in ongoing cancer clinical trials. A prevalence survey was carried out in February 1981 among 104 community hospitals and 21 member institutions to determine the characteristics of patients being treated, their staffing, and reasons why patients were not on protocol studies. The survey sampled 25 (50) consecutive patients from community hospitals (member institutions). The purpose of the study was to assess the impact of a community cancer control program. The results of the study demonstrated that 16% of patients surveyed in the affiliated community hospitals were being treated on a research protocol. In addition, a further 35% had their treatment plan influenced by a protocol. Consequently protocols have impacted directly or indirectly on 51% of the patients. The corresponding figures in member institutions were 23% and 38% for a total of 61%. In studying protocol availability, it was found that 66% of all patients were ineligible for any protocol. Of patients eligible for a protocol but not registered on one, 52% were not registered because of physician preference for a specific treatment. The affiliates surveyed were shown to be on average half as large as member institutions in terms of number of beds and staff size. Also, staff/patient ratios are generally smaller in the community hospitals. The median age of patients was considerably lower than SEER incidence data. Also, elderly patients were slightly more prevalent in community hospitals than in member institutions. A clear relationship between disease stage and age in breast cancer patients was noted with the representation of early-stage disease much higher in young women.
Collapse
|
27
|
Abstract
Melon (Cucumis melo) satellite DNA consists of two components, Q and S, each with a buoyant density in CsCl of 1.707 g/ml, but differing by 9 degrees C in "melting" temperature. These physical properties appear to be in contradiction, since both depend on G + C content. In order to resolve this anomaly, base compositions were directly determined for isolated fractions. the low-"melting" component S contains 41.8% G + C, with 6% of C present as 5-methylcytosine, whereas Q DNA contains 54% G + C, with 41% of C methylated. Analyses of restriction site loss agreed well with the direct determinations of methylation and divergence, and indicated some clustering of methylated sites in Q DNA. Analysis of restricted main-band DNA by hydridization with RNA complementary to Q satellite DNA ("Southern transfer") showed satellite Q tandem arrays interspersed in DNA of main-band density. Sequence divergence and extent of methylation did not appear to depend on whether a repeat array was present as satellite or interspersed in main-band DNA. Hydridization in situ indicated considerable heterogeneity in the genomic proportion of the Q-DNA sequences in melon fruit nuclei, implying over- and under-representation consistent with extensive unequal recombination in satellite Q tandem arrays. The cucumber, Cucumis sativus, contains less than 8% as much Q-homologous DNA per genome as the melon, suggesting rapid evolutionary gain or loss of these tandem repeat sequences.
Collapse
|
28
|
Ingle J. NATO Advanced Study Institutes Series. Series A: Life Sciences, Vol. 29 Genome Organization and Expression in Plants. Trends Biochem Sci 1980. [DOI: 10.1016/0968-0004(80)90148-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
29
|
Evans MJ, Ingle J, Molyneux MK, Sharp GT, Swain J. An occupational hygiene study of a controlled welding task using a general purpose rutile electrode. Ann Occup Hyg 1979; 22:1-17. [PMID: 543577 DOI: 10.1093/annhyg/22.1.1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
|
30
|
Abstract
Triton X-100 solubilized chloroplast DNA but not nuclear DNA from a mixture of chloroplasts and nuclei. The buoyant density of chloroplast DNA was different from that of the satellite DNA in all of the species examined (Phaseolus coccineus, Cucumis sativus, Cucumis melo, Antirrhinum majus, Vicia faba, Oenothera fruiticosa youngii). Chloroplast DNA constituted between 4.3% and 0.25% of the total leaf DNA in these species, and was present as 5 to 20 copies in each chloroplast.
Collapse
Affiliation(s)
- M J Pascoe
- Department of Botany, University of Edinburgh, Edinburgh EH9 3JH, Scotland
| | | |
Collapse
|
31
|
|
32
|
|
33
|
Abstract
A nuclear preparation, containing 60-80% of the total tissue DNA and less than 0.5% of the total rRNA, was used to characterize the nuclear RNA species synthesized in cultured artichoke explants. The half-lives of the nuclear RNA species were estimated from first-order-decay analyses to be: hnRNA (heterogeneous nuclear RNA) containing poly(A), 38 min; hnRNA lacking poly(A), 37 min; 2.5 X 10(6)-mol. wt. precursor rRNA, 24 min; 1.4 X 10(6)-mol.wt. precursor rRNA, 58 min; 1.0 X 10(6)-mol.wt. precursor rRNA, 52 min. The shorter half-lives are probably overestimates, owing to the time required for equilibration of the nucleotide-precursor pools. The pathway of rRNA synthesis is considered in terms of these kinetic measurements. The rate of accumulation of cytoplasmic polydisperse RNA suggested that as much as 40% of the hnRNA may be transported to the cytoplasm. The 14-25% of the hnRNA that contained a poly(A) tract had an average molecular size of 0.7 X 10(6) daltons. The poly(A) segment was 40-200 nucleotides long, consisted of at least 95% AMP and accounted for 8-10% of the [32P]orthophosphate incorporated into the poly(A)-containing hnRNA. Ribonucleoprotein particles released from nuclei by sonication, lysis in EDTA or incubation in buffer were analysed by sedimentation through sucrose gradients and by isopycnic centrifugation in gradients of metrizamide and CsCl. More than 50% of the hnRNA remained bound to the chromatin after each treatment. The hnRNA was always associated with protein but the densities of isolated particles suggested that the ratio of protein to RNA was lower than that reported for mammalian cells, The particles separated from chromatin were not enriched for poly(A)-containing hnRNA.
Collapse
|
34
|
Abstract
Thermal denaturation of plant ribosomal RNA followed by gel fractionation shows that although a large percentage of molecules contain breaks in the polynucleotide chain, 25S and 18S RNAs do exist as unique molecular species. Values for the rate constant of hydrolysis under routine denaturing conditions are of the order of 10(-7) to 10(-8) sec(- 1) and these are shown not to be a result of ribonuclease activity. This high rate of hydrolysis and the use of insensitive fractionation procedures may account for the reported absence of a 25S rRNA molecule and its apparent conversion to a molecule similar in size to 18S RNA.
Collapse
Affiliation(s)
- A G Hepburn
- Department of Botany, University of Edinburgh, Edinburgh, EH9 3JH, Scotland
| | | |
Collapse
|
35
|
Abstract
Heritable changes in plant weight and nuclear DNA content may be induced in certain varieties of flax by different fertilizer environments. The large stable form (L) has 16% more nuclear DNA that the small stable form (S). In subsequent generations in particular environments the nuclear DNA difference disappears, although the plant weight differences remain, while in other environments both DNA and plant weight differences are maintained. The large stable form has 56-70% more rRNA genes than the small stable form. The majority of this difference in rDNA is maintained in types where the nuclear difference has reverted. It is suggested that the expression of the flax genome may be susceptible to a reduction in the multiplicity of rRNA genes which limits the availability of protein synthetic machinery needed for growth.
Collapse
|
36
|
|
37
|
Abstract
The regulation of activity of ribosomal RNA genes has been studied in euploid and aneuploid varieties of hyacinth. The gene/gene product relationship was determined by measuring the specific gene product (stable rRNA) and the total gene product (protein) in varieties with different dosages of rRNA genes. The results show that the cellular rRNA content is positively regulated, that maximum gene utilization is not normally employed, and that the degree of utilization responds to the total genome rather than to the specific rRNA gene dosage. The mechanism of control of this regulation appears to be at the transcriptional level.
Collapse
Affiliation(s)
- J Timmis
- Department of Botany, University of Edinburgh, Mayfield Road, Edinburgh, EH9 3JH, United Kingdom
| | | |
Collapse
|
38
|
Abstract
Purified satellite DNA from melon (Cucumis melo) was shown to contain at least two components from thermal-denaturation and renaturation studies. Two components were separated after partial renaturation, a fast-renaturing fraction similar in complexity to mouse satellite DNA, and one with 6000 times greater complexity. Both components renatured very accurately, indicating a minimum of sequence divergence. Centrifugation of the purified satellite DNA in Ag+/Cs2SO4 gradients resolved two major and several minor fractions. The two major fractions were only slightly enriched for fast- or slow-renaturing sequences.
Collapse
|
39
|
Ingle J, Timmis JN, Sinclair J. The Relationship between Satellite Deoxyribonucleic Acid, Ribosomal Ribonucleic Acid Gene Redundancy, and Genome Size in Plants. Plant Physiol 1975; 55:496-501. [PMID: 16659109 PMCID: PMC541645 DOI: 10.1104/pp.55.3.496] [Citation(s) in RCA: 77] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/09/2023]
Abstract
The buoyant density of ribosomal DNA is similar in species with or without satellite DNA, and in all species examined was distinguishable from that of the satellite DNA. In melon tissues (Cucumus melo) the percentage satellite DNA is not correlated with the percentage hybridization to ribosomal RNA. Satellite DNA sequences do not appear to be dispersed between those coding for ribosomal RNA. There is no correlation between the presence of satellite DNA and high ribosomal RNA gene redundancy, but there is a correlation between satellite DNA and small genome size, which results in a correlation between satellite DNA and a high percentage hybridization to ribosomal RNA. Satellite DNAs are defined as minor components after CsCI centrifugation.
Collapse
Affiliation(s)
- J Ingle
- Department of Botany, Edinburgh University, Edinburgh, Scotland
| | | | | |
Collapse
|
40
|
Abstract
1. Artichoke tuber tissue contained RNA polymerase activity bound to the chromatin and in the supernatant after chromatin sedimentation. 2. The activity in the supernatant, the soluble polymerase, was fractionated into polymerases I and II by DEAE-cellulose chromatography, and the properties of each activity were determined. 3. The proportions of chromatin-bound and soluble activities varied with growth of the tissue, and there was a correlation between chromatin-bound activity and RNA accumulation. 4. The properties of the solubilized chromatin activity were compared with those of the soluble activity, and the relationship between these two activities is discussed.
Collapse
|
41
|
|
42
|
|
43
|
|
44
|
Abstract
The genes for cytoplasmic ribosomal RNA are partially resolved from the bulk of the DNA by CsCl equilibrium centrifugation. Although in some plants the buoyant density of the ribosomal RNA genes is as expected from the base composition of ribosomal RNA, others show a large discrepancy which cannot be due to the presence of low G-C spacer-DNA. The cross-hybridization observed with 1.3 and 0.7 x 10(6) molecular weight ribosomal RNAs and DNA, which varies greatly with different plant species, is not due to contamination of the ribosomal RNAs, and is specific for the ribosomal DNA of each species, probably largely restricted to those sequences coding for the two stable ribosomal RNAs. The double reciprocal plot may be used for the extrapolation of saturation values only with caution, because in these cases such plots are not linear over the whole of the hybridization reaction.
Collapse
Affiliation(s)
- N S Scott
- Department of Botany, Edinburgh University, Mayfield Road, Edinburgh, United Kingdom
| | | |
Collapse
|
45
|
Abstract
The aggregation of ribosomal RNA species during chromatography on methylated albumin on kieselguhr was decreased from 50 to 15% by the lower salt concentrations made possible by the use of higher pH values. The polydisperse RNA was resolved into two fractions. About 50% was eluted with the rRNA whereas the remainder was bound to the column, and was recovered only by solubilization of the methylated albumin. Both fractions of polydisperse RNA were similar in size range, but the bound fraction was considerably richer in AMP. No D-RNA (DNA-like RNA) peak was resolved under these conditions of column fractionation. However, the properties of the bound RNA were consistent with it containing both D-RNA and TB-RNA (tenaciously bound RNA). The relationship between these two fractions of AMP-rich RNA was considered. The bound RNA and ribosomal RNA responded differently to various treatments. The salt concentration required to elute ribosomal RNA was halved by increasing the pH of the fractionation, but the amount of bound RNA was in fact increased. Denaturation by hot urea decreased the binding of ribosomal RNA to the methylated albumin, but did not facilitate elution of bound RNA. The high affinity between the AMP-rich polydisperse RNA and the methylated albumin does not therefore appear to arise for the secondary structure conferred by the high AMP content.
Collapse
|
46
|
Affiliation(s)
- M Jackson
- Department of Botany, University of Edinburgh, Edinburgh, Scotland
| | | |
Collapse
|
47
|
|
48
|
|
49
|
Abstract
Instability of chloroplast rRNA has been observed with essentially all chloroplast RNA preparations. This paper describes experiments that show that, under normal conditions of preparation and fractionation, only the heavy chloroplast component (mol.wt. 1.1x10(6)) is unstable, the light chloroplast rRNA (mol.wt. 0.56x10(6)) and the cytoplasmic rRNA species (mol.wt. 1.3x10(6) and 0.70x10(6)) being stable. The stability of the 1.1x10(6)-mol. wt. molecule varies with different plant species, as also does the size and the number of fragments produced. Cleavages in three particular regions of the molecule are very frequent within the range of tissues studied. The 1.1x10(6)-mol.wt. rRNA is, however, stabilized by the presence of Mg(2+) during the preparation and fractionation of the RNA.
Collapse
|
50
|
Burns RG, Ingle J. The Relationship between the Kinetics of Ribonucleic Acid Accumulation and the Morphological Development of the Fern Gametophyte, Dryopteris borreri. Plant Physiol 1970; 46:423-8. [PMID: 16657479 PMCID: PMC396608 DOI: 10.1104/pp.46.3.423] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/08/2023]
Abstract
Fern gametophytes were grown under blue light with and without the addition of 5-fluorouracil or 8-azaguanine, and under red light. Nucleic acids were extracted by either the detergent-chloroform or the detergent-diethylpyrocarbonate method and analyzed by polyacrylamide gel electrophoresis. No significant differences in the relative distribution of the stable RNA components accompanied the transition to biplanar growth. The RNA content per average cell decreased with growth and also varied between the cultural conditions, yet it was independent of the pattern of morphological development. The falling RNA content per average cell resulted from a progressive reduction of the RNA content of the apical cell, as determined histochemically. Since filamentous growth occurred by division of this apical cell, the rate of cell division was independent of the RNA content of the dividing cell.
Collapse
Affiliation(s)
- R G Burns
- Department of Botany, King's Buildings, Edinburgh University, Edinburgh, Scotland
| | | |
Collapse
|